Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Feng, Xingmin  [Clear All Filters]
2016
Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol. 2016;3(1):e22-e29.
Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016.
2020
Zaimoku Y, Patel BA, Kajigaya S, Feng X, Alemu L, Raffo DQuinones, Groarke EM, Young NS. Deficit of circulating CD19 CD24 CD38 regulatory B cells in severe aplastic anaemia. Br J Haematol. 2020.
Chen J, Matatall KA, Feng X, Hormaechea-Agulla D, Maharjan M, Young N, King KY. Dnmt3a-null hematopoietic progenitor stem cells expand after busulfan treatment. Exp Hematol. 2020.
2021
Batey K, Kim J, Brinster L, Gonzalez-Matias G, Wu Z, Solorzano S, Chen J, Feng X, Young NS. Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells. Exp Hematol. 2021.
2022
Groarke EM, Feng X, Aggarwal N, Manley ALee Telisa, Wu Z, Gao S, Patel BA, Chen J, Young NS. Efficacy of JAK 1/2 inhibition in murine immune bone marrow failure. Blood. 2022.
2023
Wu Z, Gao S, Gao Q, Patel BA, Groarke EM, Feng X, Manley ALee, Li H, Cardona DOspina, Kajigaya S, et al. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell Rep Med. 2023;4(8):101160.